Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance

Cancer Letters

Volumn 247, Issue 1-2, 2007, Pages 40-47

  Kang, Hio Chung ^a,c   Kim, Il Jin ^a   Park, Hye Won ^a   Jang, Sang Geun ^a   Ahn, Sun A ^a   Yoon, Sang Nam ^b   Chang, Hee Jin ^c   Yoo, Byong Chul ^c   Park, Jae Gahb ^a,b,c  

^a Cancer Research Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Anticancer drugs; Drug resistance; MDK; Microarray; siRNA; Transfection

Indexed keywords

CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; PROTEIN MDK; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IC 50; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; NEOPLASMS; NERVE GROWTH FACTORS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 33845604643     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.03.017     Document Type: Article

References (31)

1. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 (2002) 615-627
2. Kang H.C., Kim I.J., Park J.H., Shin Y., Ku J.L., Jung M.S., et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin. Cancer Res. 10 (2004) 272-284
3. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., et al. Monitoring the expression profiles of doxorubicin induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60 (2000) 4161-4166
4. Dan S., Tsunoda T., Kitahara O., Yanagawa R., Zembutsu H., Katagiri T., et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62 (2002) 1139-1147
5. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24 (2000) 236-244
6. Staunton J.E., Slonim D.K., Coller H.A., Tamayo P., Angelo M.J., Park J., et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98 (2001) 10787-10792
7. Kadomatsu K., and Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204 (2004) 127-143
8. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. (Tokyo) 132 (2002) 359-371
9. O'Brien T., Cranston D., Fuggle S., Bicknell R., and Harris A.L. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res. 56 (1996) 2515-2518
10. Nakagawara A., Milbrandt J., Muramatsu T., Deuel T.F., Zhao H., Cnaan A., and Brodeur G.M. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 55 (1995) 1792-1797
11. Mishima K., Asai A., Kadomatsu K., Ino Y., Nomura K., Narita Y., et al. Increased expression of midkine during the progression of human astrocytomas. Neurosci. Lett. 233 (1997) 29-32
12. Sakitani H., Tsutsumi M., Kadomatsu K., Ikematsu S., Takahama M., Iki K., et al. Overexpression of midkine in lung tumors induced by n-nitrosobis(2-hydroxypropyl)amine in rats and its increase with progression. Carcinogenesis (London) 20 (1999) 465-469
13. Takei Y., Kadomatsu K., Itoh H., Sato W., Nakazawa K., Kubota S., and Muramatsu T. 5′-,3′-Inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J. Biol. Chem. 277 (2002) 23800-23806
14. Muramaki M., Miyake H., Hara I., and Kamidono S. Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. Clin. Cancer Res. 9 (2003) 5152-5160
15. Takei Y., Kadomatsu K., Yuasa K., Sato W., and Muramatsu T. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int. J. Cancer 114 (2005) 490-497
16. Park J.G., Kramer B.S., Steinberg S.M., Carmichael J., Collins J.M., Minna J.D., and Gazdar A.F. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res. 47 (1987) 5875-5879
17. Ferrandina G., Lauriola L., Distefano M.G., Zannoni G.F., Gessi M., Legge F., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J. Clin. Oncol. 20 (2002) 973-981
18. Casado E., Gomez-Navarro J., Yamamoto M., Adachi Y., Coolidge C.J., Arafat W.O., et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin. Cancer Res. 7 (2001) 2496-2504
19. Wesseling J.G., Yamamoto M., Adachi Y., Bosma P.J., van Wijland M., Blackwell J.L., et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 8 (2001) 990-996
20. Tang X., Sun Y.J., Half E., Kuo M.T., and Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 62 (2002) 4903-4908
21. Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F., et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann. Oncol. 13 (2002) 1205-1211
22. Saikawa Y., Sugiura T., Toriumi F., Kubota T., Suganuma K., Isshiki S., et al. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res. 24 (2004) 2723-2728
23. Mizutani Y., Nakanishi H., Li Y.N., Sato N., Kawauchi A., and Miki T. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J. Urol. 172 (2004) 1474-1479
24. Mizutani Y., Kamoi K., Ukimura O., Kawauchi A., and Miki T. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5- fluorouracil against bladder cancer. J. Urol. 168 (2002) 2650-2654
25. Sun Y., Tang X.M., Half E., Kuo M.T., and Sinicrope F.A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 62 (2002) 6323-6328
26. Hara I., Miyake H., Gleave M.E., and Kamidono S. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn. J. Cancer Res. 92 (2001) 1220-1224
27. Miyake H., Nelson C., Rennie P.S., and Gleave M.E. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60 (2000) 2547-2554
28. Chung J., Kwak C., Jin R.J., Lee C.H., Lee K.H., and Lee S.E. Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett. 203 (2004) 155-161
29. Lee C.H., Jin R.J., Kwak C., Jeong H., Park M.S., Lee N.K., and Lee S.E. Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells. Urology 60 (2002) 516-520
30. Trougakos I.P., and Gonos E.S. Functional analysis of clusterin/apolipoprotein J in cellular death induced by severe genotoxic stress. Ann. NY Acad. Sci. 1019 (2004) 206-210
31. July L.V., Beraldi E., So A., Fazli L., Evans K., English J.C., and Gleave M.E. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3 (2004) 223-232